Analyst Price Targets — SLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 28, 2024 8:03 am | Keay Nakae | Chardan Capital | $55.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $55 from $42 at Chardan |
| June 28, 2024 7:44 am | Michael Ulz | Morgan Stanley | $49.00 | $19.00 | TheFly | Silence Therapeutics price target raised to $49 from $45 at Morgan Stanley |
| March 13, 2024 11:01 am | Kostas Biliouris | BMO Capital | $67.00 | $25.61 | StreetInsider | BMO Capital Reiterates Silence Therapeutics (SLN) as Top Pick, 'buy the dip' |
| December 9, 2022 7:26 am | — | Morgan Stanley | $18.00 | $15.23 | Benzinga | Morgan Stanley Initiates Coverage On Silence Therapeutics with Equal-Weight Rating, Announces Price Target of $18 |
| November 17, 2022 8:28 am | — | Chardan Capital | $29.00 | $13.21 | Benzinga | Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $29 |
Latest News for SLN
Silence Therapeutics shares surge as investors eye key 2026 divesiran data, an advancing RNAi pipeline and progress across multiple siRNA programs.
Silence Therapeutics (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
I initiate Silence Therapeutics at a speculative Buy, driven by near-term divesiran/SLN124 catalysts in polycythemia vera (PV). SLN's mRNAi GOLD GalNAc-siRNA platform enables infrequent dosing and strong target knockdown, potentially differentiating divesiran from weekly competitors like Rusfertide. Phase 1 SANRECO data show promising phlebotomy reduction and symptom improvement, but safety and efficacy require…
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Silence Therapeutics Plc (NASDAQ:SLN) stock rose Wednesday after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive outlook for its lead drug candidate.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SLN.
U.S. House Trading
No House trades found for SLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.